Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Anastrozole
Drug ID BADD_D00142
Description Anastrozole is a non-steroidal aromatase inhibitor (AI), similar to [letrozole], used to decrease circulating estrogen levels in the treatment of postmenopausal women with estrogen-responsive breast cancer.[L8863] Anastrozole is also related to [exemestane], a steroidal AI, but its non-steroidal nature provides stark advantages including a lack of steroid-associated adverse effects such as weight gain and acne.[A186865] Aromatase inhibitors, including anastrozole, have become endocrine drugs of choice in the treatment of postmenopausal breast cancer due to a more favourable efficacy and adverse effect profile as compared to earlier estrogen receptor modulators such as [tamoxifen].[A186877,A186955] Anastrozole was first approved for use in the United States in 1995.[L8863]
Indications and Usage Anastrozole is indicated as adjunct therapy in the treatment of hormone receptor-positive early breast cancer in postmenopausal women, and as a first-line treatment for hormone receptor-positive (or hormone receptor-unknown) locally advanced or metastatic breast cancer in postmenopausal women.[L8863] It may also be used in the treatment of advanced breast cancer in postmenopausal women who experience disease progression despite treatment with [tamoxifen].[L8866,L8863]
Marketing Status approved; investigational
ATC Code L02BG03
DrugBank ID DB01217
KEGG ID D00960
MeSH ID D000077384
PubChem ID 2187
TTD Drug ID D0W0BF
NDC Product Code 38779-2555; 58623-0041; 73377-120; 65841-743; 70518-2420; 0310-0201; 51927-4435; 68071-1543; 68071-2791; 46014-1009; 69988-0013; 71052-248; 63187-080; 63629-5269; 70518-2484; 59651-236; 63850-0010; 71335-1879; 0904-6195; 46014-1160; 61200-104; 68554-0026; 16571-421; 0093-7536; 51991-620; 68382-209; 63850-6527; 50090-2453; 50090-5812; 68001-155; 65072-0702; 65129-1119; 16729-035; 42291-016; 50268-075; 60687-112; 68071-5203; 62991-3176; 43063-383; 62559-670; 72789-008; 55111-814; 62135-490; 72189-415; 53104-7627; 65096-0117; 42291-085; 76420-004; 51552-1568; 60440-2921; 62157-077; 62756-428; 82393-201
UNII 2Z07MYW1AZ
Synonyms Anastrozole | 2,2'-(5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene)bis(2-methylpropionitrile) | Anastrazole | Arimidex | ICI D1033 | ZD-1033 | ZD 1033 | Zeneca ZD 1033 | ZD1033
Chemical Information
Molecular Formula C17H19N5
CAS Registry Number 120511-73-1
SMILES CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Subacute cutaneous lupus erythematosus23.03.02.020; 15.06.02.012; 10.04.03.0120.001033%Not Available
Foot deformity15.10.03.0050.000477%Not Available
Skin plaque23.03.03.0440.000159%Not Available
Spinal pain17.10.01.020; 08.01.08.030; 15.02.01.0080.000318%Not Available
Tooth demineralisation14.04.01.016; 07.09.05.0160.000540%Not Available
Invasive ductal breast carcinoma16.10.01.013; 21.05.01.0210.000238%Not Available
Portal fibrosis24.08.06.004; 09.01.04.0080.000238%Not Available
Pseudocirrhosis16.32.03.027; 09.01.04.0090.000318%Not Available
End stage renal disease20.01.03.0190.000159%Not Available
Central nervous system vasculitis24.12.04.005; 17.08.02.029; 10.02.02.0300.000556%Not Available
Cervix carcinoma recurrent21.06.02.009; 16.12.01.0060.000159%Not Available
Epiretinal membrane06.09.03.0310.000238%Not Available
Gait inability17.02.05.069; 08.01.02.0110.000397%Not Available
Humidity intolerance08.01.09.033--Not Available
Immune thrombocytopenia10.02.01.083; 01.08.01.0130.000159%Not Available
Intestinal metastasis16.22.02.029; 07.21.01.0210.000159%Not Available
Pelvic organ prolapse21.07.04.0160.000159%Not Available
Primary biliary cholangitis10.04.09.004; 09.01.04.0100.000159%Not Available
Superior vena cava occlusion24.04.09.0040.000159%Not Available
Vaginal polyp21.08.03.011; 16.04.04.0040.000159%Not Available
Vitreoretinal traction syndrome06.09.03.0400.001192%Not Available
Vulvovaginal inflammation21.14.02.014--Not Available
The 16th Page    First    Pre   16    Total 16 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene